
drug_combination_several_time_points
compound: BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344 0.16 nM
BAY1895344 0.5 nM
BAY1895344 1.59 nM
BAY1895344 5.09 nM
BAY1895344 16.29 nM
BAY1895344 52.12 nM
BAY1895344 166.79 nM


drug_combination_several_time_points
compound: MK-1775
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775 45.7 nM
MK-1775 137.2 nM
MK-1775 411.5 nM
MK-1775 1234.6 nM
MK-1775 3703.7 nM
MK-1775 11111.1 nM
MK-1775 33333.3 nM


drug_combination_several_time_points
compound: OnlyCells
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
OnlyCells 100.0 %


drug_combination_several_time_points
compound: Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib 1.4 nM
Prexasertib 2.1 nM
Prexasertib 3.2 nM
Prexasertib 4.7 nM
Prexasertib 7.1 nM
Prexasertib 10.7 nM
Prexasertib 16.0 nM


drug_combination_several_time_points
compound: WEE1singleeffect
120
100
80
60
40
20
0
confluency (%)
0
10
20
30
40
50
60
70
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 0.16 55.69 nM_nM
BAY1895344 0.16 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
120
100
80
60
40
20
0
confluency (%)
0
10
20
30
40
50
60
70
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 0.5 55.69 nM_nM
BAY1895344 0.5 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 1.59 55.69 nM_nM
BAY1895344 1.59 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 5.09 55.69 nM_nM
BAY1895344 5.09 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
120
100
80
60
40
20
0
confluency (%)
0
10
20
30
40
50
60
70
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 16.29 55.69 nM_nM
BAY1895344 16.29 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 52.12 55.69 nM_nM
BAY1895344 52.12 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 166.79 55.69 nM_nM
BAY1895344 166.79 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 0.16 nM_nM
MK-1775 45.7 nM
BAY1895344 0.16 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 0.5 nM_nM
MK-1775 45.7 nM
BAY1895344 0.5 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 1.59 nM_nM
MK-1775 45.7 nM
BAY1895344 1.59 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 5.09 nM_nM
MK-1775 45.7 nM
BAY1895344 5.09 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 16.29 nM_nM
MK-1775 45.7 nM
BAY1895344 16.29 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 52.12 nM_nM
MK-1775 45.7 nM
BAY1895344 52.12 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 166.79 nM_nM
MK-1775 45.7 nM
BAY1895344 166.79 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 0.16 nM_nM
MK-1775 137.2 nM
BAY1895344 0.16 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 0.5 nM_nM
MK-1775 137.2 nM
BAY1895344 0.5 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 1.59 nM_nM
MK-1775 137.2 nM
BAY1895344 1.59 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 5.09 nM_nM
MK-1775 137.2 nM
BAY1895344 5.09 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 16.29 nM_nM
MK-1775 137.2 nM
BAY1895344 16.29 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 52.12 nM_nM
MK-1775 137.2 nM
BAY1895344 52.12 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 166.79 nM_nM
MK-1775 137.2 nM
BAY1895344 166.79 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 0.16 nM_nM
MK-1775 411.5 nM
BAY1895344 0.16 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 0.5 nM_nM
MK-1775 411.5 nM
BAY1895344 0.5 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 1.59 nM_nM
MK-1775 411.5 nM
BAY1895344 1.59 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 5.09 nM_nM
MK-1775 411.5 nM
BAY1895344 5.09 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 16.29 nM_nM
MK-1775 411.5 nM
BAY1895344 16.29 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 52.12 nM_nM
MK-1775 411.5 nM
BAY1895344 52.12 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 166.79 nM_nM
MK-1775 411.5 nM
BAY1895344 166.79 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 0.16 nM_nM
MK-1775 1234.6 nM
BAY1895344 0.16 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 0.5 nM_nM
MK-1775 1234.6 nM
BAY1895344 0.5 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 1.59 nM_nM
MK-1775 1234.6 nM
BAY1895344 1.59 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 5.09 nM_nM
MK-1775 1234.6 nM
BAY1895344 5.09 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 16.29 nM_nM
MK-1775 1234.6 nM
BAY1895344 16.29 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 52.12 nM_nM
MK-1775 1234.6 nM
BAY1895344 52.12 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 166.79 nM_nM
MK-1775 1234.6 nM
BAY1895344 166.79 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 0.16 nM_nM
MK-1775 3703.7 nM
BAY1895344 0.16 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 0.5 nM_nM
MK-1775 3703.7 nM
BAY1895344 0.5 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 1.59 nM_nM
MK-1775 3703.7 nM
BAY1895344 1.59 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 5.09 nM_nM
MK-1775 3703.7 nM
BAY1895344 5.09 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 16.29 nM_nM
MK-1775 3703.7 nM
BAY1895344 16.29 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 52.12 nM_nM
MK-1775 3703.7 nM
BAY1895344 52.12 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 166.79 nM_nM
MK-1775 3703.7 nM
BAY1895344 166.79 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 0.16 nM_nM
MK-1775 11111.1 nM
BAY1895344 0.16 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 0.5 nM_nM
MK-1775 11111.1 nM
BAY1895344 0.5 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 1.59 nM_nM
MK-1775 11111.1 nM
BAY1895344 1.59 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 5.09 nM_nM
MK-1775 11111.1 nM
BAY1895344 5.09 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 16.29 nM_nM
MK-1775 11111.1 nM
BAY1895344 16.29 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 52.12 nM_nM
MK-1775 11111.1 nM
BAY1895344 52.12 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
120
100
80
60
40
20
0
confluency (%)
0
10
20
30
40
50
60
70
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 166.79 nM_nM
MK-1775 11111.1 nM
BAY1895344 166.79 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 0.16 nM_nM
MK-1775 33333.3 nM
BAY1895344 0.16 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 0.5 nM_nM
MK-1775 33333.3 nM
BAY1895344 0.5 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 1.59 nM_nM
MK-1775 33333.3 nM
BAY1895344 1.59 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 5.09 nM_nM
MK-1775 33333.3 nM
BAY1895344 5.09 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 16.29 nM_nM
MK-1775 33333.3 nM
BAY1895344 16.29 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 52.12 nM_nM
MK-1775 33333.3 nM
BAY1895344 52.12 nM


drug_combination_several_time_points
compound: MK-1775_BAY1895344
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 166.79 nM_nM
MK-1775 33333.3 nM
BAY1895344 166.79 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 1.4 nM_nM
MK-1775 45.7 nM
Prexasertib 1.4 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 2.1 nM_nM
MK-1775 45.7 nM
Prexasertib 2.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 3.2 nM_nM
MK-1775 45.7 nM
Prexasertib 3.2 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 4.7 nM_nM
MK-1775 45.7 nM
Prexasertib 4.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 7.1 nM_nM
MK-1775 45.7 nM
Prexasertib 7.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 10.7 nM_nM
MK-1775 45.7 nM
Prexasertib 10.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 16.0 nM_nM
MK-1775 45.7 nM
Prexasertib 16.0 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 1.4 nM_nM
MK-1775 137.2 nM
Prexasertib 1.4 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 2.1 nM_nM
MK-1775 137.2 nM
Prexasertib 2.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 3.2 nM_nM
MK-1775 137.2 nM
Prexasertib 3.2 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 4.7 nM_nM
MK-1775 137.2 nM
Prexasertib 4.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 7.1 nM_nM
MK-1775 137.2 nM
Prexasertib 7.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 10.7 nM_nM
MK-1775 137.2 nM
Prexasertib 10.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 16.0 nM_nM
MK-1775 137.2 nM
Prexasertib 16.0 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 1.4 nM_nM
MK-1775 411.5 nM
Prexasertib 1.4 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 2.1 nM_nM
MK-1775 411.5 nM
Prexasertib 2.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 3.2 nM_nM
MK-1775 411.5 nM
Prexasertib 3.2 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 4.7 nM_nM
MK-1775 411.5 nM
Prexasertib 4.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 7.1 nM_nM
MK-1775 411.5 nM
Prexasertib 7.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 10.7 nM_nM
MK-1775 411.5 nM
Prexasertib 10.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 16.0 nM_nM
MK-1775 411.5 nM
Prexasertib 16.0 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 1.4 nM_nM
MK-1775 1234.6 nM
Prexasertib 1.4 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 2.1 nM_nM
MK-1775 1234.6 nM
Prexasertib 2.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 3.2 nM_nM
MK-1775 1234.6 nM
Prexasertib 3.2 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 4.7 nM_nM
MK-1775 1234.6 nM
Prexasertib 4.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 7.1 nM_nM
MK-1775 1234.6 nM
Prexasertib 7.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 10.7 nM_nM
MK-1775 1234.6 nM
Prexasertib 10.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 16.0 nM_nM
MK-1775 1234.6 nM
Prexasertib 16.0 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 1.4 nM_nM
MK-1775 3703.7 nM
Prexasertib 1.4 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 2.1 nM_nM
MK-1775 3703.7 nM
Prexasertib 2.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 3.2 nM_nM
MK-1775 3703.7 nM
Prexasertib 3.2 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 4.7 nM_nM
MK-1775 3703.7 nM
Prexasertib 4.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 7.1 nM_nM
MK-1775 3703.7 nM
Prexasertib 7.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 10.7 nM_nM
MK-1775 3703.7 nM
Prexasertib 10.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 16.0 nM_nM
MK-1775 3703.7 nM
Prexasertib 16.0 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 1.4 nM_nM
MK-1775 11111.1 nM
Prexasertib 1.4 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 2.1 nM_nM
MK-1775 11111.1 nM
Prexasertib 2.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 3.2 nM_nM
MK-1775 11111.1 nM
Prexasertib 3.2 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 4.7 nM_nM
MK-1775 11111.1 nM
Prexasertib 4.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 7.1 nM_nM
MK-1775 11111.1 nM
Prexasertib 7.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 10.7 nM_nM
MK-1775 11111.1 nM
Prexasertib 10.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 16.0 nM_nM
MK-1775 11111.1 nM
Prexasertib 16.0 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 1.4 nM_nM
MK-1775 33333.3 nM
Prexasertib 1.4 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 2.1 nM_nM
MK-1775 33333.3 nM
Prexasertib 2.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 3.2 nM_nM
MK-1775 33333.3 nM
Prexasertib 3.2 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 4.7 nM_nM
MK-1775 33333.3 nM
Prexasertib 4.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 7.1 nM_nM
MK-1775 33333.3 nM
Prexasertib 7.1 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 10.7 nM_nM
MK-1775 33333.3 nM
Prexasertib 10.7 nM


drug_combination_several_time_points
compound: MK-1775_Prexasertib
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 16.0 nM_nM
MK-1775 33333.3 nM
Prexasertib 16.0 nM


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 1.4 55.69 nM_nM
Prexasertib 1.4 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 2.1 55.69 nM_nM
Prexasertib 2.1 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 3.2 55.69 nM_nM
Prexasertib 3.2 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 4.7 55.69 nM_nM
Prexasertib 4.7 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 7.1 55.69 nM_nM
Prexasertib 7.1 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 10.7 55.69 nM_nM
Prexasertib 10.7 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
confluency (%)
time (h)
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 16.0 55.69 nM_nM
Prexasertib 16.0 nM
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344 0.16 nM
BAY1895344 0.5 nM
BAY1895344 1.59 nM
BAY1895344 5.09 nM
BAY1895344 16.29 nM
BAY1895344 52.12 nM
BAY1895344 166.79 nM


drug_combination_several_time_points
compound: MK-1775
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775 45.7 nM
MK-1775 137.2 nM
MK-1775 411.5 nM
MK-1775 1234.6 nM
MK-1775 3703.7 nM
MK-1775 11111.1 nM
MK-1775 33333.3 nM


drug_combination_several_time_points
compound: OnlyCells
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
relative confluency inhbition
0
10
20
30
40
50
60
70
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
OnlyCells 100.0 %


drug_combination_several_time_points
compound: Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib 1.4 nM
Prexasertib 2.1 nM
Prexasertib 3.2 nM
Prexasertib 4.7 nM
Prexasertib 7.1 nM
Prexasertib 10.7 nM
Prexasertib 16.0 nM


drug_combination_several_time_points
compound: WEE1singleeffect
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
relative confluency inhbition
0
10
20
30
40
50
60
70
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
WEE1singleeffect 55.69 nM


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 0.16 55.69 nM_nM
BAY1895344 0.16 nM
WEE1singleeffect 55.69 nM
BAY1895344 0.16 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=0.04 48.0 h=0.06 72.0 h=0.04


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 0.5 55.69 nM_nM
BAY1895344 0.5 nM
WEE1singleeffect 55.69 nM
BAY1895344 0.5 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=0.00 48.0 h=0.00 72.0 h=-0.00


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 1.59 55.69 nM_nM
BAY1895344 1.59 nM
WEE1singleeffect 55.69 nM
BAY1895344 1.59 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=0.00 48.0 h=0.00 72.0 h=-0.00


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 5.09 55.69 nM_nM
BAY1895344 5.09 nM
WEE1singleeffect 55.69 nM
BAY1895344 5.09 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=-0.02 48.0 h=0.00 72.0 h=-0.00


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 16.29 55.69 nM_nM
BAY1895344 16.29 nM
WEE1singleeffect 55.69 nM
BAY1895344 16.29 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=-0.01 48.0 h=-0.00 72.0 h=-0.00


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 52.12 55.69 nM_nM
BAY1895344 52.12 nM
WEE1singleeffect 55.69 nM
BAY1895344 52.12 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=-0.02 48.0 h=0.03 72.0 h=0.09


drug_combination_several_time_points
compound: BAY1895344_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
BAY1895344_WEE1singleeffect 166.79 55.69 nM_nM
BAY1895344 166.79 nM
WEE1singleeffect 55.69 nM
BAY1895344 166.79 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=0.18 48.0 h=0.30 72.0 h=0.33

compound: BAY1895344_WEE1singleeffect
cell line: MCF7
Time point 24 h















compound: BAY1895344_WEE1singleeffect
cell line: MCF7
Time point 48 h















compound: BAY1895344_WEE1singleeffect
cell line: MCF7
Time point 72 h
















MCF7 BI score BAY1895344_WEE1singleeffect
BAY1895344 0.16 nM WEE1singleeffect 55.69 nM
BAY1895344 0.5 nM WEE1singleeffect 55.69 nM
BAY1895344 1.59 nM WEE1singleeffect 55.69 nM
BAY1895344 5.09 nM WEE1singleeffect 55.69 nM
BAY1895344 16.29 nM WEE1singleeffect 55.69 nM
BAY1895344 52.12 nM WEE1singleeffect 55.69 nM
BAY1895344 166.79 nM WEE1singleeffect 55.69 nM
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
22.0
24.0
26.0
28.0
30.0
32.0
34.0
36.0
38.0
40.0
42.0
44.0
46.0
48.0
50.0
52.0
54.0
56.0
58.0
60.0
62.0
64.0
66.0
68.0
70.0
72.0
1.00
0.75
0.50
0.25
0.00
−0.25
−0.50
−0.75
−1.00
>0 syne; <0- anta min = -0.10 & max = 0.34


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 0.16 nM_nM
MK-1775 45.7 nM
BAY1895344 0.16 nM
MK-1775 45.7 nM BAY1895344 0.16 nM
BI_score :
24.0 h=-0.07 48.0 h=-0.04 72.0 h=-0.00


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 0.5 nM_nM
MK-1775 45.7 nM
BAY1895344 0.5 nM
MK-1775 45.7 nM BAY1895344 0.5 nM
BI_score :
24.0 h=-0.07 48.0 h=-0.06 72.0 h=-0.05


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 1.59 nM_nM
MK-1775 45.7 nM
BAY1895344 1.59 nM
MK-1775 45.7 nM BAY1895344 1.59 nM
BI_score :
24.0 h=-0.03 48.0 h=-0.03 72.0 h=-0.02


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 5.09 nM_nM
MK-1775 45.7 nM
BAY1895344 5.09 nM
MK-1775 45.7 nM BAY1895344 5.09 nM
BI_score :
24.0 h=-0.05 48.0 h=-0.06 72.0 h=-0.03


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 16.29 nM_nM
MK-1775 45.7 nM
BAY1895344 16.29 nM
MK-1775 45.7 nM BAY1895344 16.29 nM
BI_score :
24.0 h=-0.14 48.0 h=-0.08 72.0 h=-0.04


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 52.12 nM_nM
MK-1775 45.7 nM
BAY1895344 52.12 nM
MK-1775 45.7 nM BAY1895344 52.12 nM
BI_score :
24.0 h=-0.03 48.0 h=0.02 72.0 h=0.03


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 45.7 166.79 nM_nM
MK-1775 45.7 nM
BAY1895344 166.79 nM
MK-1775 45.7 nM BAY1895344 166.79 nM
BI_score :
24.0 h=-0.06 48.0 h=0.05 72.0 h=0.13


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 0.16 nM_nM
MK-1775 137.2 nM
BAY1895344 0.16 nM
MK-1775 137.2 nM BAY1895344 0.16 nM
BI_score :
24.0 h=-0.11 48.0 h=-0.08 72.0 h=-0.04


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 0.5 nM_nM
MK-1775 137.2 nM
BAY1895344 0.5 nM
MK-1775 137.2 nM BAY1895344 0.5 nM
BI_score :
24.0 h=0.02 48.0 h=-0.01 72.0 h=-0.03


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 1.59 nM_nM
MK-1775 137.2 nM
BAY1895344 1.59 nM
MK-1775 137.2 nM BAY1895344 1.59 nM
BI_score :
24.0 h=-0.01 48.0 h=-0.03 72.0 h=-0.03


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 5.09 nM_nM
MK-1775 137.2 nM
BAY1895344 5.09 nM
MK-1775 137.2 nM BAY1895344 5.09 nM
BI_score :
24.0 h=-0.03 48.0 h=-0.03 72.0 h=-0.03


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 16.29 nM_nM
MK-1775 137.2 nM
BAY1895344 16.29 nM
MK-1775 137.2 nM BAY1895344 16.29 nM
BI_score :
24.0 h=-0.05 48.0 h=-0.03 72.0 h=-0.00


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 52.12 nM_nM
MK-1775 137.2 nM
BAY1895344 52.12 nM
MK-1775 137.2 nM BAY1895344 52.12 nM
BI_score :
24.0 h=0.07 48.0 h=0.15 72.0 h=0.21


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 137.2 166.79 nM_nM
MK-1775 137.2 nM
BAY1895344 166.79 nM
MK-1775 137.2 nM BAY1895344 166.79 nM
BI_score :
24.0 h=0.28 48.0 h=0.39 72.0 h=0.42


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 0.16 nM_nM
MK-1775 411.5 nM
BAY1895344 0.16 nM
MK-1775 411.5 nM BAY1895344 0.16 nM
BI_score :
24.0 h=-0.10 48.0 h=-0.05 72.0 h=-0.01


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 0.5 nM_nM
MK-1775 411.5 nM
BAY1895344 0.5 nM
MK-1775 411.5 nM BAY1895344 0.5 nM
BI_score :
24.0 h=-0.03 48.0 h=-0.04 72.0 h=-0.03


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 1.59 nM_nM
MK-1775 411.5 nM
BAY1895344 1.59 nM
MK-1775 411.5 nM BAY1895344 1.59 nM
BI_score :
24.0 h=-0.00 48.0 h=-0.04 72.0 h=-0.05


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 5.09 nM_nM
MK-1775 411.5 nM
BAY1895344 5.09 nM
MK-1775 411.5 nM BAY1895344 5.09 nM
BI_score :
24.0 h=-0.03 48.0 h=-0.05 72.0 h=-0.05


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 16.29 nM_nM
MK-1775 411.5 nM
BAY1895344 16.29 nM
MK-1775 411.5 nM BAY1895344 16.29 nM
BI_score :
24.0 h=-0.09 48.0 h=-0.01 72.0 h=0.08


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 52.12 nM_nM
MK-1775 411.5 nM
BAY1895344 52.12 nM
MK-1775 411.5 nM BAY1895344 52.12 nM
BI_score :
24.0 h=0.13 48.0 h=0.25 72.0 h=0.35


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 411.5 166.79 nM_nM
MK-1775 411.5 nM
BAY1895344 166.79 nM
MK-1775 411.5 nM BAY1895344 166.79 nM
BI_score :
24.0 h=0.21 48.0 h=0.32 72.0 h=0.36


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 0.16 nM_nM
MK-1775 1234.6 nM
BAY1895344 0.16 nM
MK-1775 1234.6 nM BAY1895344 0.16 nM
BI_score :
24.0 h=-0.05 48.0 h=-0.01 72.0 h=0.02


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 0.5 nM_nM
MK-1775 1234.6 nM
BAY1895344 0.5 nM
MK-1775 1234.6 nM BAY1895344 0.5 nM
BI_score :
24.0 h=0.06 48.0 h=0.06 72.0 h=0.03


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 1.59 nM_nM
MK-1775 1234.6 nM
BAY1895344 1.59 nM
MK-1775 1234.6 nM BAY1895344 1.59 nM
BI_score :
24.0 h=0.06 48.0 h=-0.00 72.0 h=0.00


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 5.09 nM_nM
MK-1775 1234.6 nM
BAY1895344 5.09 nM
MK-1775 1234.6 nM BAY1895344 5.09 nM
BI_score :
24.0 h=0.05 48.0 h=0.05 72.0 h=0.05


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 16.29 nM_nM
MK-1775 1234.6 nM
BAY1895344 16.29 nM
MK-1775 1234.6 nM BAY1895344 16.29 nM
BI_score :
24.0 h=0.06 48.0 h=0.07 72.0 h=0.08


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 52.12 nM_nM
MK-1775 1234.6 nM
BAY1895344 52.12 nM
MK-1775 1234.6 nM BAY1895344 52.12 nM
BI_score :
24.0 h=0.19 48.0 h=0.21 72.0 h=0.20


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 1234.6 166.79 nM_nM
MK-1775 1234.6 nM
BAY1895344 166.79 nM
MK-1775 1234.6 nM BAY1895344 166.79 nM
BI_score :
24.0 h=0.19 48.0 h=0.18 72.0 h=0.16


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 0.16 nM_nM
MK-1775 3703.7 nM
BAY1895344 0.16 nM
MK-1775 3703.7 nM BAY1895344 0.16 nM
BI_score :
24.0 h=-0.05 48.0 h=-0.02 72.0 h=-0.00


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 0.5 nM_nM
MK-1775 3703.7 nM
BAY1895344 0.5 nM
MK-1775 3703.7 nM BAY1895344 0.5 nM
BI_score :
24.0 h=-0.06 48.0 h=-0.03 72.0 h=-0.02


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 1.59 nM_nM
MK-1775 3703.7 nM
BAY1895344 1.59 nM
MK-1775 3703.7 nM BAY1895344 1.59 nM
BI_score :
24.0 h=0.00 48.0 h=-0.01 72.0 h=-0.01


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 5.09 nM_nM
MK-1775 3703.7 nM
BAY1895344 5.09 nM
MK-1775 3703.7 nM BAY1895344 5.09 nM
BI_score :
24.0 h=-0.05 48.0 h=-0.03 72.0 h=-0.04


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 16.29 nM_nM
MK-1775 3703.7 nM
BAY1895344 16.29 nM
MK-1775 3703.7 nM BAY1895344 16.29 nM
BI_score :
24.0 h=0.03 48.0 h=0.03 72.0 h=0.03


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 52.12 nM_nM
MK-1775 3703.7 nM
BAY1895344 52.12 nM
MK-1775 3703.7 nM BAY1895344 52.12 nM
BI_score :
24.0 h=0.05 48.0 h=0.04 72.0 h=0.03


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 3703.7 166.79 nM_nM
MK-1775 3703.7 nM
BAY1895344 166.79 nM
MK-1775 3703.7 nM BAY1895344 166.79 nM
BI_score :
24.0 h=-0.01 48.0 h=0.00 72.0 h=0.00


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 0.16 nM_nM
MK-1775 11111.1 nM
BAY1895344 0.16 nM
MK-1775 11111.1 nM BAY1895344 0.16 nM
BI_score :
24.0 h=-0.08 48.0 h=-0.05 72.0 h=-0.05


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 0.5 nM_nM
MK-1775 11111.1 nM
BAY1895344 0.5 nM
MK-1775 11111.1 nM BAY1895344 0.5 nM
BI_score :
24.0 h=-0.02 48.0 h=-0.02 72.0 h=-0.02


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 1.59 nM_nM
MK-1775 11111.1 nM
BAY1895344 1.59 nM
MK-1775 11111.1 nM BAY1895344 1.59 nM
BI_score :
24.0 h=-0.02 48.0 h=-0.02 72.0 h=-0.02


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 5.09 nM_nM
MK-1775 11111.1 nM
BAY1895344 5.09 nM
MK-1775 11111.1 nM BAY1895344 5.09 nM
BI_score :
24.0 h=-0.03 48.0 h=-0.01 72.0 h=-0.01


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 16.29 nM_nM
MK-1775 11111.1 nM
BAY1895344 16.29 nM
MK-1775 11111.1 nM BAY1895344 16.29 nM
BI_score :
24.0 h=-0.01 48.0 h=-0.00 72.0 h=-0.01


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 52.12 nM_nM
MK-1775 11111.1 nM
BAY1895344 52.12 nM
MK-1775 11111.1 nM BAY1895344 52.12 nM
BI_score :
24.0 h=-0.01 48.0 h=-0.00 72.0 h=-0.00


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 11111.1 166.79 nM_nM
MK-1775 11111.1 nM
BAY1895344 166.79 nM
MK-1775 11111.1 nM BAY1895344 166.79 nM
BI_score :
24.0 h=-0.02 48.0 h=-0.01 72.0 h=-0.02


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 0.16 nM_nM
MK-1775 33333.3 nM
BAY1895344 0.16 nM
MK-1775 33333.3 nM BAY1895344 0.16 nM
BI_score :
24.0 h=-0.12 48.0 h=-0.05 72.0 h=-0.03


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 0.5 nM_nM
MK-1775 33333.3 nM
BAY1895344 0.5 nM
MK-1775 33333.3 nM BAY1895344 0.5 nM
BI_score :
24.0 h=-0.04 48.0 h=-0.02 72.0 h=-0.02


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 1.59 nM_nM
MK-1775 33333.3 nM
BAY1895344 1.59 nM
MK-1775 33333.3 nM BAY1895344 1.59 nM
BI_score :
24.0 h=-0.02 48.0 h=-0.01 72.0 h=-0.01


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 5.09 nM_nM
MK-1775 33333.3 nM
BAY1895344 5.09 nM
MK-1775 33333.3 nM BAY1895344 5.09 nM
BI_score :
24.0 h=-0.03 48.0 h=-0.02 72.0 h=-0.02


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 16.29 nM_nM
MK-1775 33333.3 nM
BAY1895344 16.29 nM
MK-1775 33333.3 nM BAY1895344 16.29 nM
BI_score :
24.0 h=-0.03 48.0 h=-0.01 72.0 h=-0.01


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 52.12 nM_nM
MK-1775 33333.3 nM
BAY1895344 52.12 nM
MK-1775 33333.3 nM BAY1895344 52.12 nM
BI_score :
24.0 h=0.02 48.0 h=0.01 72.0 h=0.01


drug_combination_several_time_points
compound: MK-1775_BAY1895344
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_BAY1895344 33333.3 166.79 nM_nM
MK-1775 33333.3 nM
BAY1895344 166.79 nM
MK-1775 33333.3 nM BAY1895344 166.79 nM
BI_score :
24.0 h=-0.03 48.0 h=-0.03 72.0 h=-0.02

compound: MK-1775_BAY1895344
cell line: MCF7
Time point 24 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 24 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 24 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 24 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 24 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 24 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 24 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 48 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 48 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 48 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 48 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 48 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 48 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 48 h
















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 72 h
relative confluency inhbition
Std Dev Img
Predicted value = 0.06 BI score = -0.00
MK-1775_BAY1895344 45.7 0.16 nM_nM
MK-1775 45.7 nM
BAY1895344 0.16 nM
Predicted value = 0.06 BI score = -0.05
MK-1775_BAY1895344 45.7 0.5 nM_nM
MK-1775 45.7 nM
BAY1895344 0.5 nM
Predicted value = 0.06 BI score = -0.02
MK-1775_BAY1895344 45.7 1.59 nM_nM
MK-1775 45.7 nM
BAY1895344 1.59 nM
Predicted value = 0.06 BI score = -0.03
MK-1775_BAY1895344 45.7 5.09 nM_nM
MK-1775 45.7 nM
BAY1895344 5.09 nM
Predicted value = 0.06 BI score = -0.04
MK-1775_BAY1895344 45.7 16.29 nM_nM
MK-1775 45.7 nM
BAY1895344 16.29 nM
Predicted value = 0.14 BI score = 0.03
MK-1775_BAY1895344 45.7 52.12 nM_nM
MK-1775 45.7 nM
BAY1895344 52.12 nM
Predicted value = 0.34 BI score = 0.13
MK-1775_BAY1895344 45.7 166.79 nM_nM
MK-1775 45.7 nM
BAY1895344 166.79 nM

compound: MK-1775_BAY1895344
cell line: MCF7
Time point 72 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 72 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 72 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 72 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 72 h















compound: MK-1775_BAY1895344
cell line: MCF7
Time point 72 h
















MCF7 BI score MK-1775_BAY1895344
MK-1775 45.7 nM BAY1895344 0.16 nM
MK-1775 45.7 nM BAY1895344 0.5 nM
MK-1775 45.7 nM BAY1895344 1.59 nM
MK-1775 45.7 nM BAY1895344 5.09 nM
MK-1775 45.7 nM BAY1895344 16.29 nM
MK-1775 45.7 nM BAY1895344 52.12 nM
MK-1775 45.7 nM BAY1895344 166.79 nM
MK-1775 137.2 nM BAY1895344 0.16 nM
MK-1775 137.2 nM BAY1895344 0.5 nM
MK-1775 137.2 nM BAY1895344 1.59 nM
MK-1775 137.2 nM BAY1895344 5.09 nM
MK-1775 137.2 nM BAY1895344 16.29 nM
MK-1775 137.2 nM BAY1895344 52.12 nM
MK-1775 137.2 nM BAY1895344 166.79 nM
MK-1775 411.5 nM BAY1895344 0.16 nM
MK-1775 411.5 nM BAY1895344 0.5 nM
MK-1775 411.5 nM BAY1895344 1.59 nM
MK-1775 411.5 nM BAY1895344 5.09 nM
MK-1775 411.5 nM BAY1895344 16.29 nM
MK-1775 411.5 nM BAY1895344 52.12 nM
MK-1775 411.5 nM BAY1895344 166.79 nM
MK-1775 1234.6 nM BAY1895344 0.16 nM
MK-1775 1234.6 nM BAY1895344 0.5 nM
MK-1775 1234.6 nM BAY1895344 1.59 nM
MK-1775 1234.6 nM BAY1895344 5.09 nM
MK-1775 1234.6 nM BAY1895344 16.29 nM
MK-1775 1234.6 nM BAY1895344 52.12 nM
MK-1775 1234.6 nM BAY1895344 166.79 nM
MK-1775 3703.7 nM BAY1895344 0.16 nM
MK-1775 3703.7 nM BAY1895344 0.5 nM
MK-1775 3703.7 nM BAY1895344 1.59 nM
MK-1775 3703.7 nM BAY1895344 5.09 nM
MK-1775 3703.7 nM BAY1895344 16.29 nM
MK-1775 3703.7 nM BAY1895344 52.12 nM
MK-1775 3703.7 nM BAY1895344 166.79 nM
MK-1775 11111.1 nM BAY1895344 0.16 nM
MK-1775 11111.1 nM BAY1895344 0.5 nM
MK-1775 11111.1 nM BAY1895344 1.59 nM
MK-1775 11111.1 nM BAY1895344 5.09 nM
MK-1775 11111.1 nM BAY1895344 16.29 nM
MK-1775 11111.1 nM BAY1895344 52.12 nM
MK-1775 11111.1 nM BAY1895344 166.79 nM
MK-1775 33333.3 nM BAY1895344 0.16 nM
MK-1775 33333.3 nM BAY1895344 0.5 nM
MK-1775 33333.3 nM BAY1895344 1.59 nM
MK-1775 33333.3 nM BAY1895344 5.09 nM
MK-1775 33333.3 nM BAY1895344 16.29 nM
MK-1775 33333.3 nM BAY1895344 52.12 nM
MK-1775 33333.3 nM BAY1895344 166.79 nM
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0 28.0 30.0 32.0 34.0 36.0 38.0 40.0 42.0 44.0 46.0 48.0 50.0 52.0 54.0 56.0 58.0 60.0 62.0 64.0 66.0 68.0 70.0 72.0
1.00
0.75
0.50
0.25
0.00
−0.25
−0.50
−0.75
−1.00
>0 syne; <0- anta min = -0.23 & max = 0.42


MCF7 BI score MK-1775_BAY1895344 24.0
BAY1895344 0.16
BAY1895344 0.5
BAY1895344 1.59
BAY1895344 5.09
BAY1895344 16.29
BAY1895344 52.12
BAY1895344 166.79
MK-1775 45.7
MK-1775 137.2
MK-1775 411.5
MK-1775 1234.6
MK-1775 3703.7
MK-1775 11111.1
MK-1775 33333.3
1.0
0.5
0.0
−0.5
−1.0
>0 syne; <0- anta min = -0.14 & max = 0.28
1.00
0.75
0.50
0.25
0.00
−0.25
−0.50
−0.75
−1.00
2.0
2.5
3.0
3.5
4.0
4.5
MK-1775
Concentration range log10 from:
[45.7 33333.3] nM
BAY1895344
Concentration range log10 from:
[0.16 166.79] nM
Bliss Score
1.0
0.5
0.0
−0.5
−1.0
>0 syne; <0- anta min = -0.14 & max = 0.28

MCF7 BI score MK-1775_BAY1895344 48.0

BAY1895344 0.16
BAY1895344 0.5
BAY1895344 1.59
BAY1895344 5.09
BAY1895344 16.29
BAY1895344 52.12
BAY1895344 166.79

MK-1775 45.7
MK-1775 137.2
MK-1775 411.5
MK-1775 1234.6
MK-1775 3703.7
MK-1775 11111.1
MK-1775 33333.3

1.0
0.5
0.0
−0.5
−1.0

>0 syne; <0- anta min = -0.08 & max = 0.39

1.00
0.75
0.50
0.25
0.00
−0.25
−0.50
−0.75
−1.00

2.0
2.5
3.0
3.5
4.0
4.5

MK-1775
Concentration range $\log_{10}$ from:
[45.7 33333.3] nM

BAY1895344
Concentration range $\log_{10}$ from:
[0.16 166.79] nM

Bliss Score

1.0
0.5
0.0
−0.5
−1.0

>0 syne; <0- anta min = -0.08 & max = 0.39


MCF7 BI score MK-1775_BAY1895344 72.0
BAY1895344 0.16
BAY1895344 0.5
BAY1895344 1.59
BAY1895344 5.09
BAY1895344 16.29
BAY1895344 52.12
BAY1895344 166.79
MK-1775 45.7
MK-1775 137.2
MK-1775 411.5
MK-1775 1234.6
MK-1775 3703.7
MK-1775 11111.1
MK-1775 33333.3
1.0
0.5
0.0
−0.5
−1.0
>0 syne; <0- anta min = -0.05 & max = 0.42
1.00
0.75
0.50
0.25
0.00
−0.25
−0.50
−0.75
−1.00
2.0
2.5
3.0
3.5
4.0
4.5
MK-1775
Concentration range log10 from:
[45.7 33333.3] nM
BAY1895344
Concentration range log10 from:
[0.16 166.79] nM
Bliss Score
1.0
0.5
0.0
−0.5
−1.0
>0 syne; <0- anta min = -0.05 & max = 0.42


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 1.4 nM_nM
MK-1775 45.7 nM
Prexasertib 1.4 nM
MK-1775 45.7 nM Prexasertib 1.4 nM
BI_score :
24.0 h=-0.21 48.0 h=-0.13 72.0 h=-0.05


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 2.1 nM_nM
MK-1775 45.7 nM
Prexasertib 2.1 nM
MK-1775 45.7 nM Prexasertib 2.1 nM
BI_score :
24.0 h=0.00 48.0 h=0.11 72.0 h=0.19


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 3.2 nM_nM
MK-1775 45.7 nM
Prexasertib 3.2 nM
MK-1775 45.7 nM Prexasertib 3.2 nM
BI_score :
24.0 h=-0.06 48.0 h=0.09 72.0 h=0.20


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 4.7 nM_nM
MK-1775 45.7 nM
Prexasertib 4.7 nM
MK-1775 45.7 nM Prexasertib 4.7 nM
BI_score :
24.0 h=0.12 48.0 h=0.30 72.0 h=0.41


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 7.1 nM_nM
MK-1775 45.7 nM
Prexasertib 7.1 nM
MK-1775 45.7 nM Prexasertib 7.1 nM
BI_score :
24.0 h=-0.03 48.0 h=0.16 72.0 h=0.29


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 10.7 nM_nM
MK-1775 45.7 nM
Prexasertib 10.7 nM
MK-1775 45.7 nM Prexasertib 10.7 nM
BI_score :
24.0 h=0.08 48.0 h=0.20 72.0 h=0.28


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 45.7 16.0 nM_nM
MK-1775 45.7 nM
Prexasertib 16.0 nM
MK-1775 45.7 nM Prexasertib 16.0 nM
BI_score :
24.0 h=0.05 48.0 h=0.14 72.0 h=0.21


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 1.4 nM_nM
MK-1775 137.2 nM
Prexasertib 1.4 nM
MK-1775 137.2 nM Prexasertib 1.4 nM
BI_score :
24.0 h=0.02 48.0 h=0.17 72.0 h=0.24


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 2.1 nM_nM
MK-1775 137.2 nM
Prexasertib 2.1 nM
MK-1775 137.2 nM Prexasertib 2.1 nM
BI_score :
24.0 h=0.14 48.0 h=0.33 72.0 h=0.45


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 3.2 nM_nM
MK-1775 137.2 nM
Prexasertib 3.2 nM
MK-1775 137.2 nM Prexasertib 3.2 nM
BI_score :
24.0 h=0.12 48.0 h=0.39 72.0 h=0.48


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 4.7 nM_nM
MK-1775 137.2 nM
Prexasertib 4.7 nM
MK-1775 137.2 nM Prexasertib 4.7 nM
BI_score :
24.0 h=0.25 48.0 h=0.47 72.0 h=0.56


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 7.1 nM_nM
MK-1775 137.2 nM
Prexasertib 7.1 nM
MK-1775 137.2 nM Prexasertib 7.1 nM
BI_score :
24.0 h=0.17 48.0 h=0.35 72.0 h=0.48


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 10.7 nM_nM
MK-1775 137.2 nM
Prexasertib 10.7 nM
MK-1775 137.2 nM Prexasertib 10.7 nM
BI_score :
24.0 h=0.19 48.0 h=0.33 72.0 h=0.38


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 137.2 16.0 nM_nM
MK-1775 137.2 nM
Prexasertib 16.0 nM
MK-1775 137.2 nM Prexasertib 16.0 nM
BI_score :
24.0 h=0.20 48.0 h=0.29 72.0 h=0.31


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 1.4 nM_nM
MK-1775 411.5 nM
Prexasertib 1.4 nM
MK-1775 411.5 nM Prexasertib 1.4 nM
BI_score :
24.0 h=-0.08 48.0 h=0.19 72.0 h=0.33


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 2.1 nM_nM
MK-1775 411.5 nM
Prexasertib 2.1 nM
MK-1775 411.5 nM Prexasertib 2.1 nM
BI_score :
24.0 h=0.18 48.0 h=0.40 72.0 h=0.53


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 3.2 nM_nM
MK-1775 411.5 nM
Prexasertib 3.2 nM
MK-1775 411.5 nM Prexasertib 3.2 nM
BI_score :
24.0 h=0.19 48.0 h=0.43 72.0 h=0.55


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 4.7 nM_nM
MK-1775 411.5 nM
Prexasertib 4.7 nM
MK-1775 411.5 nM Prexasertib 4.7 nM
BI_score :
24.0 h=0.23 48.0 h=0.45 72.0 h=0.54


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 7.1 nM_nM
MK-1775 411.5 nM
Prexasertib 7.1 nM
MK-1775 411.5 nM Prexasertib 7.1 nM
BI_score :
24.0 h=0.15 48.0 h=0.32 72.0 h=0.45


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 10.7 nM_nM
MK-1775 411.5 nM
Prexasertib 10.7 nM
MK-1775 411.5 nM Prexasertib 10.7 nM
BI_score :
24.0 h=0.19 48.0 h=0.31 72.0 h=0.36


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 411.5 16.0 nM_nM
MK-1775 411.5 nM
Prexasertib 16.0 nM
MK-1775 411.5 nM Prexasertib 16.0 nM
BI_score :
24.0 h=0.17 48.0 h=0.26 72.0 h=0.28


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 1.4 nM_nM
MK-1775 1234.6 nM
Prexasertib 1.4 nM
MK-1775 1234.6 nM Prexasertib 1.4 nM
BI_score :
24.0 h=-0.12 48.0 h=0.05 72.0 h=0.10


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 2.1 nM_nM
MK-1775 1234.6 nM
Prexasertib 2.1 nM
MK-1775 1234.6 nM Prexasertib 2.1 nM
BI_score :
24.0 h=0.09 48.0 h=0.18 72.0 h=0.23


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 3.2 nM_nM
MK-1775 1234.6 nM
Prexasertib 3.2 nM
MK-1775 1234.6 nM Prexasertib 3.2 nM
BI_score :
24.0 h=0.11 48.0 h=0.20 72.0 h=0.22


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 4.7 nM_nM
MK-1775 1234.6 nM
Prexasertib 4.7 nM
MK-1775 1234.6 nM Prexasertib 4.7 nM
BI_score :
24.0 h=0.14 48.0 h=0.22 72.0 h=0.22


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 7.1 nM_nM
MK-1775 1234.6 nM
Prexasertib 7.1 nM
MK-1775 1234.6 nM Prexasertib 7.1 nM
BI_score :
24.0 h=0.04 48.0 h=0.10 72.0 h=0.16


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 10.7 nM_nM
MK-1775 1234.6 nM
Prexasertib 10.7 nM
MK-1775 1234.6 nM Prexasertib 10.7 nM
BI_score :
24.0 h=0.18 48.0 h=0.17 72.0 h=0.15


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 1234.6 16.0 nM_nM
MK-1775 1234.6 nM
Prexasertib 16.0 nM
MK-1775 1234.6 nM Prexasertib 16.0 nM
BI_score :
24.0 h=0.06 48.0 h=0.08 72.0 h=0.08


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 1.4 nM_nM
MK-1775 3703.7 nM
Prexasertib 1.4 nM
MK-1775 3703.7 nM Prexasertib 1.4 nM
BI_score :
24.0 h=-0.08 48.0 h=0.01 72.0 h=0.02


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 2.1 nM_nM
MK-1775 3703.7 nM
Prexasertib 2.1 nM
MK-1775 3703.7 nM Prexasertib 2.1 nM
BI_score :
24.0 h=-0.06 48.0 h=-0.00 72.0 h=0.01


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 3.2 nM_nM
MK-1775 3703.7 nM
Prexasertib 3.2 nM
MK-1775 3703.7 nM Prexasertib 3.2 nM
BI_score :
24.0 h=-0.03 48.0 h=0.03 72.0 h=0.04


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 4.7 nM_nM
MK-1775 3703.7 nM
Prexasertib 4.7 nM
MK-1775 3703.7 nM Prexasertib 4.7 nM
BI_score :
24.0 h=-0.03 48.0 h=0.02 72.0 h=0.03


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 7.1 nM_nM
MK-1775 3703.7 nM
Prexasertib 7.1 nM
MK-1775 3703.7 nM Prexasertib 7.1 nM
BI_score :
24.0 h=-0.04 48.0 h=-0.01 72.0 h=0.01


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 10.7 nM_nM
MK-1775 3703.7 nM
Prexasertib 10.7 nM
MK-1775 3703.7 nM Prexasertib 10.7 nM
BI_score :
24.0 h=-0.08 48.0 h=-0.04 72.0 h=-0.05


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 3703.7 16.0 nM_nM
MK-1775 3703.7 nM
Prexasertib 16.0 nM
MK-1775 3703.7 nM Prexasertib 16.0 nM
BI_score :
24.0 h=-0.02 48.0 h=-0.02 72.0 h=-0.02


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 1.4 nM_nM
MK-1775 11111.1 nM
Prexasertib 1.4 nM
MK-1775 11111.1 nM Prexasertib 1.4 nM
BI_score :
24.0 h=-0.11 48.0 h=-0.04 72.0 h=-0.02


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 2.1 nM_nM
MK-1775 11111.1 nM
Prexasertib 2.1 nM
MK-1775 11111.1 nM Prexasertib 2.1 nM
BI_score :
24.0 h=-0.03 48.0 h=-0.00 72.0 h=0.01


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 3.2 nM_nM
MK-1775 11111.1 nM
Prexasertib 3.2 nM
MK-1775 11111.1 nM Prexasertib 3.2 nM
BI_score :
24.0 h=-0.05 48.0 h=-0.01 72.0 h=0.01


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 4.7 nM_nM
MK-1775 11111.1 nM
Prexasertib 4.7 nM
MK-1775 11111.1 nM Prexasertib 4.7 nM
BI_score :
24.0 h=-0.02 48.0 h=0.01 72.0 h=0.02


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 7.1 nM_nM
MK-1775 11111.1 nM
Prexasertib 7.1 nM
MK-1775 11111.1 nM Prexasertib 7.1 nM
BI_score :
24.0 h=-0.07 48.0 h=-0.04 72.0 h=-0.01


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 10.7 nM_nM
MK-1775 11111.1 nM
Prexasertib 10.7 nM
MK-1775 11111.1 nM Prexasertib 10.7 nM
BI_score :
24.0 h=-0.04 48.0 h=-0.03 72.0 h=-0.02


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 11111.1 16.0 nM_nM
MK-1775 11111.1 nM
Prexasertib 16.0 nM
MK-1775 11111.1 nM Prexasertib 16.0 nM
BI_score :
24.0 h=-0.07 48.0 h=-0.05 72.0 h=-0.05


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 1.4 nM_nM
MK-1775 33333.3 nM
Prexasertib 1.4 nM
MK-1775 33333.3 nM Prexasertib 1.4 nM
BI_score :
24.0 h=-0.10 48.0 h=-0.04 72.0 h=-0.02


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 2.1 nM_nM
MK-1775 33333.3 nM
Prexasertib 2.1 nM
MK-1775 33333.3 nM Prexasertib 2.1 nM
BI_score :
24.0 h=-0.03 48.0 h=-0.01 72.0 h=-0.00


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 3.2 nM_nM
MK-1775 33333.3 nM
Prexasertib 3.2 nM
MK-1775 33333.3 nM Prexasertib 3.2 nM
BI_score :
24.0 h=-0.00 48.0 h=0.01 72.0 h=0.02


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 4.7 nM_nM
MK-1775 33333.3 nM
Prexasertib 4.7 nM
MK-1775 33333.3 nM Prexasertib 4.7 nM
BI_score :
24.0 h=-0.03 48.0 h=-0.01 72.0 h=-0.00


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 7.1 nM_nM
MK-1775 33333.3 nM
Prexasertib 7.1 nM
MK-1775 33333.3 nM Prexasertib 7.1 nM
BI_score :
24.0 h=-0.08 48.0 h=-0.04 72.0 h=-0.03


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 10.7 nM_nM
MK-1775 33333.3 nM
Prexasertib 10.7 nM
MK-1775 33333.3 nM Prexasertib 10.7 nM
BI_score :
24.0 h=-0.04 48.0 h=-0.04 72.0 h=-0.04


drug_combination_several_time_points
compound: MK-1775_Prexasertib
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
MK-1775_Prexasertib 33333.3 16.0 nM_nM
MK-1775 33333.3 nM
Prexasertib 16.0 nM
MK-1775 33333.3 nM Prexasertib 16.0 nM
BI_score :
24.0 h=-0.06 48.0 h=-0.05 72.0 h=-0.05

compound: MK-1775_Prexasertib
cell line: MCF7
Time point 24 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 24 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 24 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 24 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 24 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 24 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 24 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 48 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 48 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 48 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 48 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 48 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 48 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 48 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 72 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 72 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 72 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 72 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 72 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 72 h















compound: MK-1775_Prexasertib
cell line: MCF7
Time point 72 h
















MCF7 BI score MK-1775_Prexasertib
MK-1775 45.7 nM Prexasertib 1.4 nM
MK-1775 45.7 nM Prexasertib 2.1 nM
MK-1775 45.7 nM Prexasertib 3.2 nM
MK-1775 45.7 nM Prexasertib 4.7 nM
MK-1775 45.7 nM Prexasertib 7.1 nM
MK-1775 45.7 nM Prexasertib 10.7 nM
MK-1775 45.7 nM Prexasertib 16.0 nM
MK-1775 137.2 nM Prexasertib 1.4 nM
MK-1775 137.2 nM Prexasertib 2.1 nM
MK-1775 137.2 nM Prexasertib 3.2 nM
MK-1775 137.2 nM Prexasertib 4.7 nM
MK-1775 137.2 nM Prexasertib 7.1 nM
MK-1775 137.2 nM Prexasertib 10.7 nM
MK-1775 137.2 nM Prexasertib 16.0 nM
MK-1775 411.5 nM Prexasertib 1.4 nM
MK-1775 411.5 nM Prexasertib 2.1 nM
MK-1775 411.5 nM Prexasertib 3.2 nM
MK-1775 411.5 nM Prexasertib 4.7 nM
MK-1775 411.5 nM Prexasertib 7.1 nM
MK-1775 411.5 nM Prexasertib 10.7 nM
MK-1775 411.5 nM Prexasertib 16.0 nM
MK-1775 1234.6 nM Prexasertib 1.4 nM
MK-1775 1234.6 nM Prexasertib 2.1 nM
MK-1775 1234.6 nM Prexasertib 3.2 nM
MK-1775 1234.6 nM Prexasertib 4.7 nM
MK-1775 1234.6 nM Prexasertib 7.1 nM
MK-1775 1234.6 nM Prexasertib 10.7 nM
MK-1775 1234.6 nM Prexasertib 16.0 nM
MK-1775 3703.7 nM Prexasertib 1.4 nM
MK-1775 3703.7 nM Prexasertib 2.1 nM
MK-1775 3703.7 nM Prexasertib 3.2 nM
MK-1775 3703.7 nM Prexasertib 4.7 nM
MK-1775 3703.7 nM Prexasertib 7.1 nM
MK-1775 3703.7 nM Prexasertib 10.7 nM
MK-1775 3703.7 nM Prexasertib 16.0 nM
MK-1775 11111.1 nM Prexasertib 1.4 nM
MK-1775 11111.1 nM Prexasertib 2.1 nM
MK-1775 11111.1 nM Prexasertib 3.2 nM
MK-1775 11111.1 nM Prexasertib 4.7 nM
MK-1775 11111.1 nM Prexasertib 7.1 nM
MK-1775 11111.1 nM Prexasertib 10.7 nM
MK-1775 11111.1 nM Prexasertib 16.0 nM
MK-1775 33333.3 nM Prexasertib 1.4 nM
MK-1775 33333.3 nM Prexasertib 2.1 nM
MK-1775 33333.3 nM Prexasertib 3.2 nM
MK-1775 33333.3 nM Prexasertib 4.7 nM
MK-1775 33333.3 nM Prexasertib 7.1 nM
MK-1775 33333.3 nM Prexasertib 10.7 nM
MK-1775 33333.3 nM Prexasertib 16.0 nM
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0 28.0 30.0 32.0 34.0 36.0 38.0 40.0 42.0 44.0 46.0 48.0 50.0 52.0 54.0 56.0 58.0 60.0 62.0 64.0 66.0 68.0 70.0 72.0
1.00
0.75
0.50
0.25
0.00
−0.25
−0.50
−0.75
−1.00
>0 syne; <0- anta min = -0.35 & max = 0.56

MCF7 BI score MK-1775_Prexasertib 24.0





>0 syne; <0- anta min = -0.21 & max = 0.25

>0 syne; <0- anta min = -0.21 & max = 0.25


MCF7 BI score MK-1775_Prexasertib 48.0
Prexasertib 1.4
Prexasertib 2.1
Prexasertib 3.2
Prexasertib 4.7
Prexasertib 7.1
Prexasertib 10.7
Prexasertib 16.0
MK-1775 45.7
MK-1775 137.2
MK-1775 411.5
MK-1775 1234.6
MK-1775 3703.7
MK-1775 11111.1
MK-1775 33333.3
1.0
0.5
0.0
−0.5
−1.0
>0 syne; <0- anta min = -0.13 & max = 0.47
1.00
0.75
0.50
0.25
0.00
−0.25
−0.50
−0.75
−1.00
2.0
2.5
3.0
3.5
4.0
4.5
MK-1775
Concentration range log10 from:
[45.7 33333.3] nM
Prexasertib
Concentration range log10 from:
[1.4 16.0] nM
Bliss Score
1.0
0.5
0.0
−0.5
−1.0
>0 syne; <0- anta min = -0.13 & max = 0.47


MCF7 BI score MK-1775_Prexasertib 72.0
Prexasertib 1.4
Prexasertib 2.1
Prexasertib 3.2
Prexasertib 4.7
Prexasertib 7.1
Prexasertib 10.7
Prexasertib 16.0
MK-1775 45.7
MK-1775 137.2
MK-1775 411.5
MK-1775 1234.6
MK-1775 3703.7
MK-1775 11111.1
MK-1775 33333.3
1.0
0.5
0.0
−0.5
−1.0


>0 syne; <0- anta min = -0.05 & max = 0.56
MK-1775
Concentration range log10 from:
[45.7 33333.3] nM
2.0
2.5
3.0
3.5
4.0
4.5
Prexasertib
Concentration range log10 from:
[1.4 16.0] nM
1.00
0.75
0.50
0.25
0.00
−0.25
−0.50
−0.75
−1.00
Bliss Score
1.0
0.5
0.0
−0.5
−1.0

>0 syne; <0- anta min = -0.05 & max = 0.56


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 1.4 55.69 nM_nM
Prexasertib 1.4 nM
WEE1singleeffect 55.69 nM
Prexasertib 1.4 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=-0.10 48.0 h=0.01 72.0 h=0.05


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 2.1 55.69 nM_nM
Prexasertib 2.1 nM
WEE1singleeffect 55.69 nM
Prexasertib 2.1 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=0.05 48.0 h=0.16 72.0 h=0.24


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 3.2 55.69 nM_nM
Prexasertib 3.2 nM
WEE1singleeffect 55.69 nM
Prexasertib 3.2 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=-0.08 48.0 h=0.10 72.0 h=0.18


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 4.7 55.69 nM_nM
Prexasertib 4.7 nM
WEE1singleeffect 55.69 nM
Prexasertib 4.7 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=0.04 48.0 h=0.26 72.0 h=0.37


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
relative confluency inhbition
time (h)
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 7.1 55.69 nM_nM
Prexasertib 7.1 nM
WEE1singleeffect 55.69 nM
Prexasertib 7.1 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=0.15 48.0 h=0.32 72.0 h=0.44


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 10.7 55.69 nM_nM
Prexasertib 10.7 nM
WEE1singleeffect 55.69 nM
Prexasertib 10.7 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=0.08 48.0 h=0.23 72.0 h=0.30


drug_combination_several_time_points
compound: Prexasertib_WEE1singleeffect
relative confluency inhbition
time (h)
1.5
1.0
0.5
0.0
−0.5
−1.0
−1.5
0
10
20
30
40
50
60
70
MCF7 10K/well
Std Dev Img
Control_DMSO_combination 0.34 %
Prexasertib_WEE1singleeffect 16.0 55.69 nM_nM
Prexasertib 16.0 nM
WEE1singleeffect 55.69 nM
Prexasertib 16.0 nM WEE1singleeffect 55.69 nM
BI_score :
24.0 h=0.03 48.0 h=0.18 72.0 h=0.23

compound: Prexasertib_WEE1singleeffect
cell line: MCF7
Time point 24 h















compound: Prexasertib_WEE1singleeffect
cell line: MCF7
Time point 48 h















compound: Prexasertib_WEE1singleeffect
cell line: MCF7
Time point 72 h
















MCF7 BI score Prexasertib_WEE1singleeffect
Prexasertib 1.4 nM WEE1singleeffect 55.69 nM
Prexasertib 2.1 nM WEE1singleeffect 55.69 nM
Prexasertib 3.2 nM WEE1singleeffect 55.69 nM
Prexasertib 4.7 nM WEE1singleeffect 55.69 nM
Prexasertib 7.1 nM WEE1singleeffect 55.69 nM
Prexasertib 10.7 nM WEE1singleeffect 55.69 nM
Prexasertib 16.0 nM WEE1singleeffect 55.69 nM
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0 28.0 30.0 32.0 34.0 36.0 38.0 40.0 42.0 44.0 46.0 48.0 50.0 52.0 54.0 56.0 58.0 60.0 62.0 64.0 66.0 68.0 70.0 72.0
1.00
0.75
0.50
0.25
0.00
−0.25
−0.50
−0.75
−1.00
>0 syne; <0- anta min = -0.17 & max = 0.44


compound: BAY1895344
cell line: MCF7
Time: 24 h
Time: 48 h
Time: 72 h
(%) confluency
concentration range log10 from: [0.16 ; 166.79] nM
IC_15 Value outside the tested range!
EC_50Not possible to calculate
IC_50 Value outside the tested range!
Emax = 89.58 % confluency
LL4=> fit_curve, R² = 0.2880 X² = 162.7 Sum of squares = 246.69
IC_15 = 94.68 nM
EC_50 = 88.87 nM
IC_50 Value outside the tested range!
Emax = 77.48 % confluency
LL4=> fit_curve, R² = 0.7296 X² = 3652.4 Sum of squares = 247.16
experiment_data
IC_15 = 74.25 nM
EC_50 = 86.14 nM
IC_50 Value outside the tested range!
Emax = 70.37 % confluency
LL4=> fit_curve, R² = 0.9385 X² = 73.4 Sum of squares = 64.86
experiment_data


compound: MK-1775
cell line: MCF7
Time: 24 h
Time: 48 h
Time: 72 h
(%) confluency
concentration range log10 from: [45.7 ; 33333.3] nM
IC_15 = 922.43 nM
EC_50 = 1951.45 nM
IC_50 = 3058.75 nM
Emax = 31.27 % confluency
LL4=> fit_curve, R2 = 0.9881 X2 = 23.1 Sum of squares = 73.46
experiment_data
IC_15 = 505.01 nM
EC_50 = 1267.66 nM
IC_50 = 1676.48 nM
Emax = 21.95 % confluency
LL4=> fit_curve, R2 = 0.9940 X2 = 1.9 Sum of squares = 49.31
experiment_data
IC_15 = 458.00 nM
EC_50 = 1049.47 nM
IC_50 = 1276.21 nM
Emax = 17.80 % confluency
LL4=> fit_curve, R2 = 0.9983 X2 = 1.4 Sum of squares = 17.06
experiment_data


compound: Prexasertib
cell line: MCF7
Time: 24 h
Time: 48 h
Time: 72 h
(%) confluency
concentration range log10 from: [1.4 ; 16.0] nM
IC_15 = 5.86 nM
EC_50Not possible to calculate
IC_50 Value outside the tested range!
Emax = 78.29 % confluency
LL4=> fit_curve, R2 = 0.5939 X2 = 124.9 Sum of squares = 150.49
IC_15 = 4.85 nM
EC_50Not possible to calculate
IC_50 Value outside the tested range!
Emax = 63.30 % confluency
LL4=> fit_curve, R2 = 0.8715 X2 = 375489.3 Sum of squares = 142.56
IC_15 = 6.13 nM
EC_50 = 8.46 nM
IC_50 Value outside the tested range!
Emax = 56.53 % confluency
LL4=> fit_curve, R2 = 0.9678 X2 = 6.7 Sum of squares = 54.55
experiment_data